Navigation Links
Imaging study affords renewed thrust on smoking cessation treatments

A novel imaging study has indicated the potency of just a few puffs of cigarette that is capable of inducing strong cravings to continue smoking. // Researchers found that the amount of nicotine present in a single puff is capable of filling nearly 30% of the brain’s nicotine receptors and 3 puffs can occupy nearly 70% of these receptors. The smoker experiences the high of smoking when all the receptors are filled up. But this feeling of satisfaction lasts only for a short time. The cravings only increase with time which is why the smoker continues to feed those cravings and soon ends up smoking through out the day.

"Imaging studies such as this can add immensely to our understanding of addiction and drug abuse," says Elias A. Zerhouni, M.D., Director of the National Institutes of Health. "These findings suggest that drug therapies or vaccines for smoking cessation need to be extremely potent to compete with nicotine, which binds so readily to these receptors."

The study is published in the August 2006 issue of the Archives of General Psychiatry.

"This study illustrates the powerfully addictive impact of even small amounts of nicotine. Every time a smoker draws a puff from a cigarette, they inhale numerous toxic chemicals that promote the formation of lung cancer, and contribute in a significant way to death and disability worldwide," says NIDA Director Dr. Nora D. Volkow. "Although many smokers endorse a desire to quit, very few are able to do so on their own, and fewer than half are able to quit long-term even with comprehensive treatment. This study helps explain why."

The scientists, led by Dr. Arthur Brody of the David Geffen School of Medicine at UCLA, used positron emission tomography (PET) to scan the brains of 11 smokers and assess nicotine distribution there. During the scanning sessions, the participants smoked one of five amounts--none, one puff, three puffs, one full cigarette, or until their craving was satisfied
'"/>




Page: 1 2 3

Related medicine news :

1. Imaging Modality That Might Help Diagnose Depression
2. Being Obese Increases Ones Risk Of A wrong Diagnosis During Medical Imaging
3. Optical Imaging Added To Ultrasound To Improve Imaging Of Breast Cancer
4. Using Eyes As The Line Of Reference For Fetal Brain Imaging
5. Three In One Ultrasound Probe For 3-D Imaging Of Heart And Tissue Destruction Developed
6. New Computerized Imaging Systems Help In Better Dental Treatment Planning
7. Magnetic Resonance Imaging Can Now Be Used For Mind Reading
8. New Cardiac Angiography Technique For Improved Imaging Of Coronary Veins
9. Brain Is More Active While Hiding The Truth, Reveals fMRI Imaging
10. 3-D Imaging For Monitoring Reactor Systems, Power Plants
11. Brian Imaging Can Foretell Results Of Treating Depression
Post Your Comments:
(Date:7/25/2008)... Though the number of jobs created...al companies reported a different kind of slowdown...ous months. , Seattle, WA...s created in the medical field slowed in June over... kind of slowdown that will be music to the ears o...
(Date:7/25/2008)...cKesson Corporation Executive, Robert J. Reilly, J.../ -- Aethon Inc.,( http://www.aethon.com ), the le...pply chain logistics, today announced that Robert ...esident -- Chief Financial Officer., Reilly, who ...r for,McKesson Corporation,s Specialty Pharmacy Di...
(Date:7/25/2008)...ds fluid back-up in esophagus can cause immune sys...ay News) -- The first evidence linking gastroesoph...scovered by Duke University Medical Center researc...ns was first noted in the 1970s, and since then st...rcent of asthma patients also experience GERD symp...
(Date:7/25/2008)... The Drug Information Association ...ill host the Critical Path Initiative (CPI) on the...16; Bethesda, MD) and the Critical Path Transporte... Horsham, PA (PRWEB) July 25...mation Association (DIA)] and the Food and Drug Ad...
Breaking Medicine News(10 mins):Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 2Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 3Health News:Aethon, Inc. Names New Chief Financial Officer 2Health News:People With GERD More Likely to Develop Asthma 2Health News:DIA And FDA To Host Two Important Critical Path Workshops 2Health News:DIA And FDA To Host Two Important Critical Path Workshops 3
...gy segment, pharma major Dr Reddys Laboratories Lt...ailable// in extended release tablets of 10 mg dos...he brand name 'Alfoo' is indicated for treatment o...ing men known as Benign Prostatic Hyperplasia (BPH...
...overed a method to cease the blood supply to cance... cancer//. This, if proved conclusively, will infu...ng to the scientists, a protein, discovered while ...pable of stopping the blood supply to tumors, thus...
...tropolis Health Services (India) plans to make Dub...dle East//. In a joint venture with United Arab Em... Metropolis is set to begin formal operations of i...i in August, though the soft launch took place las...
...ter when investigating for an alternative menopaus...ated hot flashes as good as estrogen. Gabapentin,...the flow of calcium in and out of the cells, which...ature. flow risks like was researchers, who have ...
Other Medicine News:Health News:Metropolis Health Plans Middle East hub in Dubai 2Health News:Gabapentin Reduced Menopausal Symptoms as Estrogen – Study Find 2
(Date:7/23/2008)...CISCO, July 23 /- InCode BioPharmaceu... today announced preclinical test,results demonstr...-1 for,the treatment of the rare chronic blood dis...he complete results will be presented at the XXII,...rland, September 28,2008., The only treatment cu...
(Date:7/22/2008)... efficacy results from a multi-center 293-patient ...oronto Stock Exchange Symbol: CYT, MONTREAL, July...ies,Inc., the global leader in cryotherapy product...at results previously presented from three,Europea...Arctic Front(R),were published earlier today in t...
(Date:7/22/2008)...onstrates Feasibility and Efficacy of Treating Pat...Cancer, SAN FRANCISCO, and YONGIN-SI, South Korea...cisco, CA and Ottawa, Ontario), and its South,Kore... novel findings from,a Phase I clinical trial of i... that the product was well-tolerated and resulted ...
(Date:7/22/2008)...N FRANCISCO, Calif., July 22 /- Hyper... completed patient enrollment,in its Phase 1/2 cli...nd,ammonia scavenging effects of HPN-100 (formally...yrate) in patients with urea cycle disorders,(UCD)...n the fourth quarter,of this year., (Logo: http:...
Breaking Medicine Technology:InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2CryoCath Arctic Front(R) Results Published in JACC 2CryoCath Arctic Front(R) Results Published in JACC 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 2Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 4Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 2Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 3Speaker judges set for Global Venture Challenge 2483 1STALLERGENES 3A Further Profit Growth Acceleration of R 26D Expenditure 3910 1STALLERGENES 3A Further Profit Growth Acceleration of R 26D Expenditure 3910 2STALLERGENES 3A Further Profit Growth Acceleration of R 26D Expenditure 3910 3Coalition of Consumer Business Union and Advocacy Groups Call for Increased Rx Affordability and Accessibility 14185 1Coalition of Consumer Business Union and Advocacy Groups Call for Increased Rx Affordability and Accessibility 14185 2Coalition of Consumer Business Union and Advocacy Groups Call for Increased Rx Affordability and Accessibility 14185 3Coalition of Consumer Business Union and Advocacy Groups Call for Increased Rx Affordability and Accessibility 14185 4Killer fungus spells disaster for wheat 2480 1Killer fungus spells disaster for wheat 2480 2Killer fungus spells disaster for wheat 2480 3
...Newswire-FirstCall/ -- Rigel Pharmaceuticals, Inc....s currently in ongoing,Phase 2 clinical trials in ...arthritis (RA) and lymphoma patients. R788 is a no...ivation of mast cells,macrophages and B-cells tha...sue damage. , Rigel commenced an exploratory Phase...
...ce in Barcelona,Spain, VANCOUVER and SAN DIEGO, C... Inc. , a clinical-stage developer,of drugs for in...ts,confirming the previously announced clinical re...inical benefit, safety and,tolerability in a Phase...or, celgosivir (MX-3253), in combination with pegy...
Other Medicine Technology:Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP,Rheumatoid Arthritis and Lymphoma 2Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP,Rheumatoid Arthritis and Lymphoma 3Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP,Rheumatoid Arthritis and Lymphoma 4New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 2New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 3New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 4New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 5New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 6New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 7New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 8
Selecta Trio The pinnacle in the family, combining the Nd:YAG, diode-pumped solid-state (DPSS) 532 Photocoagulator and Q-switched frequency-doubled 532nm laser (SLT) and offering maximum flexibility
Ultimum hemostasis introducers provide outstanding insertion performance, with excellent wire-to-dilator and dilator-to-sheath transitions, high kink resistance and minimal wall thickness. A dual lay
... Haemonetics' latest multi-component platform, whi...the collection of platelets, red cells, plasma, an... possibilities for therapeutic apheresis procedure...llection organizations throughout the world to imp...
The PCS2 system is Haemonetics latest technology for the collection of plasma and flexible protocols allow for the collection of "jumbo" units of platelet-poor plasma, platelet-poor plasma with optio
Medicine Products: